StemCells, Inc. (NASDAQ:STEM)

CAPS Rating: 2 out of 5

A biopharmaceutical company that operates in one segment, the development of novel cell-based therapeutics designed to treat human diseases and disorders.

Recs

0
Player Avatar Gerf1 (21.37) Submitted: 9/20/2011 10:07:57 AM : Outperform Start Price: $2.38 STEM Score: -79.08

this research will be very beneficial to help humans in so many ways, should also make $$$ if succesufull and managed correctly, and used for good not bad.

Featured Broker Partners


Advertisement